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Pharmacologic suppression of the effector phase of contact 
hypersensitivity appears to have major relevance with regard 
to treatment of type IV reactions like contact dermatitis. 
Recently, tumor necrosis factor a has been shown to be a 
critical mediator in hapten-induced irritant and contact hy-
persensitivity reactions, thus off~rin~ new possibilities, !or 
therapeutic inte~entlon. Pentoxlfyllme, a methyl~antll1ne 
derivative used 111 the treatment of vascular disorders, 
currently has been found to suppress the production of tumor 
necrosis factor a by human and murine leukocytes. There-
fore, the effect of pentoxifylline on the elicitation phase of 
contact hypersensitivity was studied. Intraperitoneal injec-
tion of pentoxifylline into sensitized Balb/c and C3H/HeN 
mice before application of the challenging hapten dose re-
C ontact dermatitis is a complex skin disorder that af-fects numerous patients. It comprises either an irri-tant or an allergic mechanism, the latter distin-guished by the demonstration of a delayed-type allergy in the affected individual. Besides its remark-
able frequency, contact dermatitis can be a disabling disorder, par-
ticularly in the chronic stage. Avoidance o~ the allergen, if.dete~ted, 
is not always practicable; in such cases corticosteroids applIed either 
topically or systemically are the major therapy, bearing the risk, 
however, oflong-term Side effects. Therefore, development of new 
therapeutic strategies influencing contact hypersensitivity (CHS) 
reactions is of major importance. 
Recently, tumor necrosis factor (TNF) a has been identifi~d a~ a 
critical mediator in hapten-induced irritant and contact senSItiVity 
reactions [1]. In particular, injection of TN Fa antibodies into sensi-
tized mice before application of the challenging dose of the respec-
tive hapten abrogated the ear-swelling response significantly. Al-
though these observations contribute to the fur~he.r unders.tandtng 
of the effector phase of CHS, their therapeutic ImplIcatIOns are 
limited because injection of TNFa antibodies cannot be seriously 
considered for practical treatment of contact dermatitis in humans at 
present. . . ' . 
Pentoxifylline (PTX) IS a methylxanthtne denvatlve that has 
been used therapeutically for quite a long time in a huge number of 
patients suffering from vascular disorders [2]. PTX is thought to 
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suited in a significant reduction of the outcome of the contact 
hy~ersensitivity reaction. The suppressive effect of pentoxi-
~~Im~ was dose dependent and maximally pronounced upon 
lIBectlOn 3 h before hapten application. In contrast to the 
effector phase of contact hypersensitivity, induction of con-
~a~t hyp~rsensit~vity ~as not affected by pentoxifylline when 
mJected mto naive mice before performance of sensitization. 
In addition, irritant dermatitis induced by 1 % croton oil or 
5% benzalkonium chloride was suppressed by pentoxifylline 
as w~ll. These data suggest a potential pharmacologic inter-
ventIOn with pentoxifylline as a means to treat contact der-
matitis. Key words: contact hypersensitivity /pentoxifylline/ 
tumor necrosis factor a/suppression/irritant reaction.] Invest 
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reduce the blood viscosity and to increase the filterability of blood 
cells, which results in a rise in capillary blood flow. Besides its 
hemorheol~gic activity, PTX recently has been found to suppress 
the P:OduCtlOll of TN Fa by murine and human leukocytes [3,4] . In 
addItton, It can counteract TNF stimulation of human granulo-
cytes [5]. 
Acc.ording to the observations that TNFa seems to be of impor-
tance 111 the effector phase of CHS [1] and that PTX can antagonize 
T.NFa production a?d activity, respectively [3-5], PTX may ex-
lublt the capacity to 1l1fluence contact dermatitis. Therefore, in the 
present study, we investigated whether PTX is able to suppress the 
effector phase of the murine CHS model. 
MATERIALS AND METHODS 
Mice Balb/c and C3H/HeN mice were purchased from the Versuchstier-
zuchtanstalt Hannover, FRG, or from the Versuchstierzllchtanstalt Him-
berg, Austria. 
Co~tact Hypersensitivity Mice were sensitized by painting 25 pI of 
0.5 Vo 2,4-dll1ltro-flllorobenzene (DNF13; Sigma Corp., St. Louis, MO) so-
lution (acetone: ohve 011,4: 1) on the razor-shaved abdomen on days 1 and 2 
as reported preVIOusly [6l: On day 6 the left ear was challenged by applying 
20 pI 0.3% DNFB; the.nght ear was treated with acetone/olive oil alone. 
Th~ degree of ear swe1lll1g was measured with a spring-loaded micrometer 
(Mltutoyo, Japan). CHS was determined as the amount of swelling of the 
hapten-challenged left ear compared to the thickness of the vehicle (ace-
to,:,;: ohve Oll)-treatednght ear in sensitized animals and expressed in cm X 
10 or as percentage ll1crease ear swelling. Negative controls consisted of 
mice that were ear challenged without prior sensitization. In some experi-
ments, oxazolone (Sigma) was used (25 pI 0.8% for sensitization and 20 pI 
0.3% for challenge). Each treatment group consisted of at least seven ani-
mals, and each experiment was performed at least three times. 
Irritant Dermatitis For induction of irritant dermatitis 20 pI of 1 % cro-
ton od (Serva, Heidelberg, FRG) dissolved in acetone were applied on the 
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Table I . Effect of PTX on the Elicitation Phase of CHS 
Mice Sensitization' Challenge' Treatment' % Ear Swelling' 
Balb/c DNFB (0.3%) 2.1 ± 3.7 
Balb/c DNFB (0.5%) DNFB (0.3%) 51.4 ± 15.7 
Balb/c DNFB (0.5%) DNFB (0.3%) PTX 14.1 ±7.4' 
Balb/c Oxazolone (0.3%) 0.5 ± 1.6 
Balb/c Oxazolone (0.8%) Oxazolone (0.3%) 34.5 ± 11.5 
Balb/c Oxazolone (0.8%) Oxazolone (0.3%) PTX 12.7 ± 9.2' 
C3H/HeN DNFB (0.3%) 3.3 ± 4.3 
C3H/HeN DNFB (0.5%) DNFB (0.3%) 29.7 ± 9.2 
C3H/HeN DNFB (0.5%) DNFB (0.3%) PTX 8.0 ± 7.2' 
, Hapten was applied Oil the razor-shaved abdomen on days 1 and 2. 
• Hapten was applied Oil the left ear on day 6. 
, PTX (50 mg/kg body weight) was injected interperitoneally 3 h before performance of challenge. 
d CHS is expressed as the percentage increase (mean ± SO) of the thickness of the challenged left ear compared to the thickness of the untreated right ear. Ear thickness 
(mean ± SO) of the untreated control was 19.3 ± 1.1 elll X 10-'. 
'Significantly different from positive control (p < 0.001). 
left ear. Ear swell ing was measured 8 h after irritant application with a 
spring-loaded micrometer. Irritant reaction was determined as the amount 
of swelling of the irritant-treated left ear compared to the thickness of the 
vehicle (acetone)-treated right ear and expressed in cm X 10-'. As a further 
irritant, benzalkonium ch loride (Sigma) was used dissolved in acetone at a 
concentration of 5%. Irritant application and measurement was performed as 
with croton oil. 
Injection of PTX PTX (Dr. Rentschler Comp., Laupheim, Germany) 
dissolved in sodium chloride was i,*cted intraperitoneally, the usual dose 
being 50 mg/kg body weight unless otherwise stated. Control mice were 
injected intraperitoneally with the equal volume (100 j.d) of physiologic 
sodium ch loride solution, which, however, had absolutely no effect on the 
olltcome of both the sensitization and challenge procedure. 
Histology The ears were fixed in buffered formaldehyde, embedded in 
parafin, sectioned, and stained with hematoxylin-eosin. 
Statistical Analysis Statistical analysis was performed by the lise of 
the Student t test. Differences below p < 0.05 were regarded as signifi-
cant. 
RESULTS 
Intraperitoneal injection of 50 mg/kg PTX 3 h before DNFB chal-
lenge into DNFB-sensitized Balb/c mice resulted in a significant 
reduction of ear swelling, whereas intraperitoneal application of 
sodium ch loride as a control had no effect (Table I) . Application of 
DNFB to the ears of sensitized mice caused both epidermal and 
dermal al terations, in particular necrosis of keratinocytes, edema, 
hemorrhage, and leukocyte infiltration (Fig 1A). Administration of 
PTX prevented both the dermal and epidermal component of the 
CHS reaction (Fig IB). Similar results were obtained when oxazo-
lone was used instead of DNFB (Table 1). The inhibitory effect of 
PTX on the effector phase of CHS was not strain specific, because 
comparable data were obtained with C3H/HeN mice (Table I). To 
determine whether the time lag between PTX injection and per-
formance of ear challenge is of relevance, PTX was injected at 1, 3, 
6, 12, or 24 h before challenge. The optimal suppressive effect was 
observed when PTX was applied 3 h before challenge (Fig 2) . The 
inhibitory activity ofPTX was dose dependent, yielding maximum 
suppression at a concentration of 50 mg/kg body weight (Fig 3). To 
study whether PTX also affects the induction phase of CHS, PTX 
was injected intraperitoneally into naive Balb/(; mice 3 h before 
sensitization with 0.5% DNFB and challenge was performed 5 d 
later. PTX-treated mice, however, did not differ in their ear swell-
ing response from that of positive control mice (Table II), suggest-
ing that under these conditions PTX does not affect the induction 
phase of CHS. To investigate whether PTX also suppresses irritant 
reactions, PTX was injected intraperitoneally into Balb/c mice 3 h 
before application of 1 % croton oil on the left ear. In contrast to 
mice treated with 1 % croton oil only, ear swelling was found re-
duced in PTX-pretreated mice (9 .3 ± 3.0 versus 5.2 ± 2.2 cm X 
10- 3 , P < 0.05). Similar results were obtained when benzalkonium 
chloride was used as an irritant (10.2 ± 3.1 versus 6.1 ± 4.4 cm X 
10-', P < 0.05). 
DISCUSSION 
PTX, a methylxanthine known for many years for its hemorheo lo_ 
gic properties, recently has been found to prevent multiple organ 
failure and acute respiratory distress syndrome induced by lipopoly_ 
saccharide or recombinant TNFa and IL-2, respectively, in animals 
[7 -9). PTX also has been shown to reduce the release of TNFa 
8 
Figure 1. Ear sections from DNFB-sensitized mice (Balb/c) killed 24 h 
after application of challenging dose of DNFB. Mice were injected with 
physiologic sodium chloride (A) or with PTX intraperitoneally (B) 3 h 
before application of the challenging dose. In A, the dermis is edematous and 
infiltrated with leukocytes. In addition, necrotic cells are detectable with in 
the epidermis and the hair fo ll icles (-» . In B, no changes are found in the 
epidermis and only a slight inflammatory infi ltrate is detectable within the I 
dermis. Bar, 20 j.lm. 
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Figure 2. T ime kinetics. PTX (50 mgjkg body ~eight) was injected intra-
'coneaJly into Balbjc mIce at the tIme pomts mdlcated before perform-;~:~ of ear challenge. Ear swel ling was evaluated 24 h later as the thickness 
of the left ear minus the thickness of the untreated n ght ear and ~xpressed as 
em X 10-3 (mean ± SO). Negative control consIsts of unsensltlzed mIce 
h t were ear challenged only. Experiments were repeated at least three 
t. a es' results show one representative experiment. " Significantly different tIm , 
from positive control (p < 0.001) . 
fter Injection of endotoxin to healthy human volunteers or to 
a uinea pigs [10,11] . In the present study, the effect of PTX on the ~ffecto r phase of CHS was investigated. The rationale for tha ~ was 
based on a recent report showing that TNFa seems to. be a ~ntlcal 
media tor during this event [1]. Thep;esent data provIde ~vldence 
chat PTX indeed is able to prevent ehCItatl?n of CHS reaction. The 
effect of PTX is dose dependent and maxl11~ally pronounced uIJon 
intraperitoneal inj ection 3 h before applicatIOn of the challengmg 
dose . Most experiments were performed WIth DNFB as the sensI-
tizing agent; however, the suppressive effect of PTX was also o~-
rved when oxazolone was used. In addition, the effect of PTX IS 
seo t strain specific because similar data were obtained when using ~alb / c and C3H/~eN mice. PTX had no effe~t on the outc~me of 
nsitization when l11Jected 3 h before applicatIOn of the senSltlzmg ~e se into naive mice, suggesting thac it does not affect th e induction ~ase. However, one cannot exclude a suppressive activity of PTX ~nder other experimental conditions, e.g., injection at other time 
points or at hi gher doses. 
The inhibitory effect of PTX on the effector phase of CHS, 
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Figure 3. Oose kinetics. PTX was il~ected intraperitoneally at the concell-
trations indicated into ONFB-sensltlzed Balbjc mlCe. Three hours later 
chall enge was performed on the left ear. Ear ~we ll ing was evaluated 24 h 
later as the thickness of the left ear mlllUS the tlllckness of the untreated nght 
ear and expressed as em X 10- 3 (mean ± SO). Negati~e control consists of 
unsensitized mice that were ear challenged only. Expeflmcnts were rel:'eated 
at least three times; results show one representative experiment. "Slgmfi-
candy different from positive control (p < 0.01). 























0.2 ± 0.4 
60.7 ± 13.8 
PTX 51.7 ± 19.8' 
0,8 ± 0.7 
27.3 ± 14.0 
PTX 29.0 ± 7.4' 
• Hapten was applied on the razor-shaved abdomen on days 1 and 2, 
, H apten was applied on the left car on day 6, 
, PTX (50 mgjkg body weight) was injected interperiw nca lly 3 h before perform-
ance of sensitization on days 1 and 2, respectively. 
J CHS is expressed as the percentage increase (mean ± SD) of the thickness of the 
challenged left car compared to the thickness of the untreated right car. Ear thickness 
(mean ± SD) untreated control was 20. 1 ± 1.6 em X 10- 3 • 
• N ot significantl y different from positive control. 
however, does not seem to be strictly specific, in that irritant derma-
titis induced by 1 % croton oil and 5% benzalkonium chloride, re-
spectively, were reduced by PTX as well . This may suggest that 
similar mechanisms are involved. These data are comparable to 
findings of Piguet et af showing that TNFa is of relevance in pri-
mary irritant reactions induced by hapten application [1]. Morpho-
logic similarities between irritant and CHS reactions suggest in-
volvement of the same effector mechanisms, in which TNFa is 
regarded to playa key role [1]. The same seems to be true also for 
other conditions, like graft-versus-host disease, cerebral malaria, 
BCG granu loma formation, and other granulomatous and fibrotic 
processes [12 -16]. Whereas in these reactions T lymphocytes and 
macrophages are supposed to be the major source of TNFa, in 
hapten-induced irritant and hypersensitivity reactions keratinocytes 
are found to express increased amounts of TN Fa [1]. 
PTX is a methylxanthine derivative that functions as a phospho-
dies terase inhibitor [17]. PTX is well known for its hemorheologic 
properties attributed to its influence of red-cell deformability , 
plasma viscosity, and platelet reactivity [2]. Recently, it was shown 
that PTX blocks LPS-induced macrophage-derived TNFa at the 
mRNA and protein level [3] . Because other methylxanthines and 
diburyryl cAMP have similar effects on TNF expression, the mech-
anism of this suppression is supposed to be Ilia the generation of 
intracell ular cAMP [3]. In addition, it was recentl y found that PTX 
blocks TNF mRNA accumulation in murine macrophages, but, in 
contrast to dexamethasone, has no effect on the efficacy of transla-
tion [1 8]. Keratinocytes currently have been described to produce 
TNFa [1 9] and thus appear to be a likely source of this mediator in 
irritant and CHS reactions [1] . Therefore, at present we are studying 
whether the inhibitory effect of PTX on TNFa release is also ob-
served with keratinocytes ill " itro. 
Whether suppression of TN Fa by PTX is in fact responsible for 
the blocking of the effector phase of CHS cannot be answered 
definitely by the present study. Although our data are in good ac-
cordance with those showing TN Fa to be a critical mediator during 
these events [1] , other mechanisms may be involved. For example, 
adhesion molecule expression (CD 11 a, CD 11 b, CD 11 c, CD 18) 
has been found to be downregulated by PTX, resulting in a de-
creased granulocyte-adhesive function, possibly diminishing the in-
flammatory response in C HS reaction [20]. This assumption is sup-
ported by the observation that antibodies directed against such 
adhesion structures diminish C HS and irritant reactions [1] . In addi-
tion, PTX may directly affect endothelial cells. These alternative 
mechanisms have to be considered in light of a recent paper show-
ing that TNFa antibodies suppress the induction of CHS while 
being ineffective when given after sensitization [21]. These data are 
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in sharp contrast to those by Piguet et al [1] and there. is no good 
explanation for this discrepancy at present. However, differences m 
the dose, preparation, or specificity of the respective antibody may 
account for the different observations. 
In conclusion, the present study demonstrates that PTX can sup-
press the effector phase of CHS and thus raises new pharmacologic 
questions about the treatment of CHS reac~ions. It remains to be 
determined whether PTX can only functIOn preventatlve!y, or 
whether it is also curative, i.e., inhibitory when given after adminis-
tration of the hapten. Although the mechanisms of action involved 
are not yet clear, it is interesting to speculate on the potential phar-
macologic intervention possible with PTX or its derivatives as a 
means to treat contact dermatitis. This is also supported by the fact 
that PTX, a drug with well-known pharmakokinetics and safety, 
has been used therapeutically in humans with vascular disorders for 
more than a decade, without major side effects. 
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